UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
August 13, 2024 16:06 ET
|
Firefly Neuroscience, Inc.
Firefly Neuroscience CEO Issues Letter to Stockholders
Following Closing of Merger and Listing on Nasdaq
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
August 12, 2024 08:30 ET
|
Oragenics
– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
August 08, 2024 08:45 ET
|
Oragenics
SARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
July 10, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
June 27, 2024 08:30 ET
|
Oragenics
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Closing of Public Offering
June 26, 2024 16:47 ET
|
Oragenics
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Pricing of Public Offering
June 25, 2024 08:30 ET
|
Oragenics
SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Proposed Public Offering
June 24, 2024 18:43 ET
|
Oragenics
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
June 20, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
May 22, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...